{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:21:42Z","timestamp":1791897702497,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.urology.2014.02.034","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T09:47:32Z","timestamp":1398764852000},"page":"117-121","source":"Crossref","is-referenced-by-count":44,"title":["Solifenacin Is Able to Improve the Irritative Symptoms After Transurethral Resection of Bladder Tumors"],"prefix":"10.1016","volume":"84","author":[{"given":"Zhensheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongchao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2014.02.034_bib1","series-title":"Cancer Facts and Figures\u00a02011","year":"2012"},{"key":"10.1016\/j.urology.2014.02.034_bib2","unstructured":"American Urological Association. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update. Available at: https:\/\/www.auanet.org\/education\/guidelines\/bladder-cancer.cfm. Accessed February 18, 2010."},{"key":"10.1016\/j.urology.2014.02.034_bib3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1442-2042.2010.02556.x","article-title":"Transurethral resection of the bladder tumour (TURBT) for non-muscle invasive bladder cancer: basic skills","volume":"17","author":"Furuse","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2014.02.034_bib4","series-title":"Campbell-Walsh Urology","first-page":"9790","author":"Alan","year":"2007"},{"key":"10.1016\/j.urology.2014.02.034_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","article-title":"Complications of intravesical chemotherapy","volume":"19","author":"Thrasher","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2014.02.034_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/nau.20870","article-title":"Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence","volume":"29","author":"Abrams","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2014.02.034_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.urology.2011.11.050","article-title":"Efficacy of gabapentin for prevention of postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor","volume":"79","author":"Bala","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.urology.2014.02.034_bib8","series-title":"Campbell-Walsh Urology","first-page":"9832","author":"Alan","year":"2007"},{"key":"10.1016\/j.urology.2014.02.034_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/bja\/ael003","article-title":"Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study","volume":"96","author":"Agarwal","year":"2006","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.urology.2014.02.034_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2014.02.034_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejphar.2004.03.044","article-title":"In\u00a0vitro and in\u00a0vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats","volume":"492","author":"Ohtake","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.urology.2014.02.034_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1248\/bpb.30.54","article-title":"Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents","volume":"30","author":"Ohtake","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.urology.2014.02.034_bib13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1742-1241.2006.01067.x","article-title":"Solifenacin significantly improves all symptoms of overactive bladder syndrome","volume":"60","author":"Chapple","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2014.02.034_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A\u00a0comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2014.02.034_bib15","series-title":"Guidelines on Urological Diseases","first-page":"29","year":"2011"},{"key":"10.1016\/j.urology.2014.02.034_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2010.06.044","article-title":"Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score","volume":"77","author":"Homma","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2014.02.034_bib17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1213\/01.ane.0000167775.46192.e9","article-title":"The efficacy of tolterodine for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study","volume":"101","author":"Agarwal","year":"2005","journal-title":"Anesth Analg"},{"key":"10.1016\/j.urology.2014.02.034_bib18","doi-asserted-by":"crossref","first-page":"854697","DOI":"10.1155\/2011\/854697","article-title":"Comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, parallel-group trial (the LIST Study)","volume":"2011","author":"Zaitsu","year":"2011","journal-title":"Adv Urol"},{"key":"10.1016\/j.urology.2014.02.034_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2014.02.034_bib20","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","article-title":"Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer","volume":"53","author":"Hendricksen","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2014.02.034_bib21","first-page":"CD003781","article-title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults","volume":"18","author":"Nabi","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urology.2014.02.034_bib22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2014.02.034_bib23","first-page":"2825","article-title":"Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency","volume":"182","author":"Kaplan","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2014.02.034_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0302-2838(01)00009-4","article-title":"Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review","volume":"41","author":"Rovner","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2014.02.034_bib25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.urology.2014.02.034_bib26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"10.1016\/j.urology.2014.02.034_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1464-410X.83.s2.11.x","article-title":"Diagnostic assessment of the overactive bladder during the filling phase: the detrusor activity index","volume":"83","author":"van Waalwijk van Doorn","year":"1999","journal-title":"BJU Int"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429514002398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429514002398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T03:21:13Z","timestamp":1716693673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429514002398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0090429514002398"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2014.02.034","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}